Disarib showed better activity on the TP53-mutated metastatic TNBC cell lines and undifferentiated cells with cancer stem-like properties than the TP53 wildtype cell line MCF7 (Supplementary Figure S1b.i–ii). This evidence concerns the gene TP53 and cancer.